Two top executives at Summit Therapeutics Inc. (SMMT) have made significant share purchases, signaling strong confidence in the company. On June 4, 2026, Co-Chief Executive Officers Robert W. Duggan and Mahkam Zanganeh each acquired 100,000 shares.
The transactions, priced at $14.60 per share, represent an investment of approximately $1.46 million for each executive, bringing the total insider buy to around $2.92 million. This coordinated buying activity among senior leadership is often viewed as a particularly bullish indicator within the investment community.
The purchases by the Co-CEOs suggest a high degree of conviction in Summit Therapeutics' current valuation and future prospects. Such actions by individuals with intimate knowledge of the company's operations are closely watched by investors.